Coverage
-
April 21, 2016
Pharmaceutical company iBio Inc. settled a putative securities class action in Delaware federal court Thursday, agreeing to pay roughly $1.87 million and attorneys' fees for allegedly fabricating a joint venture to manufacture an Ebola treatment in an effort to pump up the company's value at a time when the disease was ravaging Africa.
1 other articles on this case.
View all »